<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877016</url>
  </required_header>
  <id_info>
    <org_study_id>PI2018_843_0028</org_study_id>
    <nct_id>NCT03877016</nct_id>
  </id_info>
  <brief_title>Pilot Study in Order to Evaluate Disconfort Among Outpatients Using actiTENS for Neuropathic Pain vs TENS ECO 2.</brief_title>
  <acronym>QolTENS</acronym>
  <official_title>Prospective, Multicentric, Randomized on Two Arms, Controlled, by Cross-over, Pilot Study, in Order to Evaluate Disconfort Among Outpatients Using actiTENS for Neuropathic Pain vs TENS ECO 2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-pharmacological treatments for pain relief are more and more used in clinical care
      although any scientific validation. Among the non-pharmacological treatments of neuropathic
      pain relief, TENS (Electrical Nerve Stimulation Therapy) is the major treatment with the best
      benefit. Unfortunately, the use of TENS by patients appears very difficult. Because of this
      inconvenience, more than 40% of TENS users interrupt the treatment despite treatment benefit.
      A new TENS device: actiTENS that seems to be less constraining than TENS is now available in
      France. ActiTENS efficacy and safety compared to TENS need to be investigated.

      The main objective is to evaluate and to compare the use of actiTENS, with TENS Eco 2, the
      classical device in patients with chronic neuropathic pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disconfort of using TENS (Electrical Nerve Stimulation Therapy) Eco2 versus actiTENS</measure>
    <time_frame>day7 after patient inclusion</time_frame>
    <description>Discomfort evaluation will be determined by using VAS (Visual Analogue Scale)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disconfort of using TENS (Electrical Nerve Stimulation Therapy) Eco2 versus actiTENS</measure>
    <time_frame>day 35 after patient inclusion</time_frame>
    <description>Discomfort evaluation will be determined by using VAS (Visual Analogue Scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>length of TENS daily use</measure>
    <time_frame>day7 after patient inclusion</time_frame>
    <description>Length of TENS daily use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of TENS daily use</measure>
    <time_frame>day 35 after patient inclusion</time_frame>
    <description>Length of TENS daily use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>TENS Eco2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TENS Eco2 is the classical device in patients with chronic neuropathic pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>actiTENS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ActiTENS is a new TENS device, that seems less cotraining.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TENS</intervention_name>
    <description>TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation</description>
    <arm_group_label>TENS Eco2</arm_group_label>
    <arm_group_label>actiTENS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult

          -  Patient covered by national health insurance

          -  Patient able to express consent

          -  Patient with neuropathic pain with DN4 (Douleur Neuropathique 4 Questions) &gt; or =
             4/10.

          -  Actual or potential neurologic lesion

          -  Patient still using a TENS device

        Exclusion Criteria:

          -  Planned surgery in the next two months

          -  Modification of the reatment in the next two motnhs

          -  Other study ongoing for the patient

          -  Medical contraindication for TENS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric SERRA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Amiens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric SERRA, MD</last_name>
    <phone>(33)322668820</phone>
    <email>serra.eric@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ERIC SERRA</last_name>
      <email>serra.eric@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropathic pain</keyword>
  <keyword>electrical nerve stimulation therapy</keyword>
  <keyword>patient report outcomes</keyword>
  <keyword>non-pharmalogical treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

